

**Statement of Standalone Audited Financial Results for the Quarter & Year Ended on 31/03/2017**

PART-I						(Rs. In Lacs except EPS)
Sr. No.	Particulars	3 months ended	Preceding 3 months ended	Corresponding 3 months ended in the previous year	Year to date figures for the current period ended	Previous year ended
		31/03/2017	31/12/2016	31/03/2016	31/03/2017	31/03/2016
		Audited	Unaudited	Audited	Audited	Audited
1	<b>Income from Operations</b>					
(a)	Net Sales/Income from Operations (Net of excise duty)	2720.61	2485.05	2191.15	10290.17	9294.13
(b)	Other Operating Income	19.44	5.61	7.02	40.42	64.37
	<b>Total income from Operations (net)</b>	<b>2740.05</b>	<b>2490.66</b>	<b>2198.17</b>	<b>10330.59</b>	<b>9358.50</b>
2	<b>Expenses</b>					
(a)	Cost of Materials Consumed	254.63	229.24	113.95	804.25	670.25
(b)	Purchase of Stock-in-trade	654.16	709.25	464.48	2447.12	2218.59
(c)	Changes in inventories of Finished Goods, Work-in Progress and Stock-in-trade	-174.68	-220.05	42.72	-195.45	-120.80
(d)	Employee benefit expenses	605.44	644.80	557.27	2425.69	2149.02
(e)	Depreciation and Amortisation Expense	44.82	45.13	54.82	178.71	199.17
(f)	other expenses	831.71	690.63	749.03	2874.85	2795.56
	<b>Total Expenses</b>	<b>2216.08</b>	<b>2099.01</b>	<b>1982.26</b>	<b>8535.17</b>	<b>7911.79</b>
3	Profit from operations before other income, finance costs and exceptional items (1-2)	<b>523.97</b>	<b>391.65</b>	<b>215.91</b>	<b>1795.42</b>	<b>1446.71</b>
4	other income	88.38	65.87	87.73	276.42	273.40
5	Profit from ordinary activities before finance costs and exceptional items (3 + 4)	<b>612.35</b>	<b>457.52</b>	<b>303.64</b>	<b>2071.84</b>	<b>1720.11</b>
6	Finance Costs	12.62	8.55	12.07	40.99	37.81
7	Profit from ordinary activities after finance costs but before exceptional items (5 - 6)	<b>599.73</b>	<b>448.97</b>	<b>291.56</b>	<b>2030.85</b>	<b>1682.30</b>
8	Exceptional Items	0.40	-0.52	0.54	12.78	0.54
9	Profit from ordinary activities before tax (7 + 8)	<b>600.13</b>	<b>448.46</b>	<b>292.10</b>	<b>2043.63</b>	<b>1682.83</b>
10	Tax Expense	246.74	153.35	162.73	697.18	604.93
11	Net Profit from ordinary activities after tax (9 - 10)	<b>353.39</b>	<b>295.11</b>	<b>129.37</b>	<b>1346.45</b>	<b>1077.90</b>
12	Extraordinary items	0.00	0.00	0.00	0.00	0.00
13	Net Profit for the period (11 + 12)	<b>353.39</b>	<b>295.11</b>	<b>129.37</b>	<b>1346.45</b>	<b>1077.90</b>
14	Paid-up equity share capital (F.V. Rs. 10/- each)	464.93	464.93	464.93	464.93	464.93
15	Reserve excluding Revaluation Reserves as at balance sheet date.	0.00	0.00	0.00	4900.39	3553.94
16	Earnings Per Share (before and after extraordinary items) Basic and Diluted	7.60	6.35	2.78	28.96	23.18


*Shil M. Bhat*


Science hai toh Hope hai Hope hai toh Health hai Health hai toh Happiness hai





Standalone Statement of Assets and Liabilities			
Particulars		As at 31/03/2017 (Rs. in lacs)	As at 31/03/2016 (Rs. in lacs)
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
1	<b>Share Holders' Fund</b>		
	(a) Share Capital	464.93	464.93
	(b) Reserves & Surplus	4900.39	3553.94
	(c) Money received against share warrants	0.00	0.00
	<b>Sub - Total - Share Holders' Fund</b>	<b>5365.32</b>	<b>4018.87</b>
2	<b>Share Application Money Pending Allotment</b>		
3	<b>Minority Interest</b>		
4	<b>Non Current Liabilities</b>		
	(a) Long Term Borrowings	24.13	24.61
	(b) Deferred Tax Liability (Net)	50.32	63.14
	(c) Other Long Term Liabilities	292.74	287.91
	(d) Long Term Provisions	37.29	0.00
	<b>Sub -Total - Non Current Liabilities</b>	<b>404.48</b>	<b>375.66</b>
5	<b>Current Liabilities</b>		
	(a) Short Term Borrowings	613.36	517.31
	(b) Trade Payables	601.62	330.26
	(c) Other Current Liabilities	544.56	467.46
	(d) Short Term Provisions	32.74	93.35
	<b>Sub -Total - Current Liabilities</b>	<b>1792.28</b>	<b>1408.38</b>
	<b>Total - Equity &amp; Liabilities</b>	<b>7562.08</b>	<b>5802.91</b>
<b>B</b>	<b>ASSETS</b>		
1	<b>Non Current Assets</b>		
	(a) Fixed Assets	1062.64	1210.65
	(b) Goodwill on Consolidation	0.00	0.00
	(c) Non Current Investments	115.25	61.33
	(d) Deferred Tax Assets (Net)	0.00	0.00
	(e) Long Term Loans & Advances	0.00	0.00
	(f) Other Non Current assets	0.00	0.00
	<b>Sub-Total - Non Current Assets</b>	<b>1177.89</b>	<b>1271.98</b>
2	<b>Current Assets</b>		
	(a) Current Investments	0.00	0.00
	(b) Inventories	1074.57	823.84
	(c) Trade Receivables	907.18	577.66
	(d) Cash & Cash Equivalents	4208.40	2963.53
	(e) Short Term Loans & Advances	64.47	52.69
	(f) Other Current Assets	129.57	113.20
	<b>Sub - Total - Current Assets</b>	<b>6384.19</b>	<b>4530.93</b>
	<b>Total - Assets</b>	<b>7562.08</b>	<b>5802.91</b>


**Notes:**

- The above audited financial results for the year ended on 31.03.2017 were taken on record by the audit committee and board of directors of the company at their respective meetings held on 30<sup>th</sup> May 2017
- The company is dealing exclusively in Pharmaceuticals business segment, hence segmentwise reporting is not applicable.
- The Board of Directors have recommended a dividend of Rs.8.10 (81%) per equity shares of Rs.10/- each.
- The figures for the quarter ended March 31, 2017 are the balancing figure between the audited figures in respect of the Audited full financial year and the unaudited published year to date figures upto the third quarter of the financial year 2016-17, which were subject to limited review by the statutory Auditors of the Company.
- The figures of previous quarters/year have been reclassified / regrouped / rearranged wherever necessary.

Place : Mumbai

Date : 30<sup>th</sup> May, 2017

By order of the Board  
For Jenburkt Pharmaceuticals Ltd.

  
(Ashish U. Bhuta)

Chairman and Managing Director

Science hai ton Hope hai Hope hai ton Health hai Health hai ton Happiness hai